Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy

BACKGROUND: Methyl-aminolevulinate photodynamic therapy (MAL-PDT) is an excellent option for the treatment of basal cell carcinoma (BCC). However, up to 25% of cases are resistant to this treatment modality. OBJECTIVE: The aim of this study was to identify potential biomarkers of BCC response to MAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Gracia-Cazaña, Tamara, Mascaraque, Marta, Lucena, Silvia Rocío, Vera-Álvarez, Jesús, González, Salvador, Juarranz, Ángeles, Gilaberte, Yolanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481917/
https://www.ncbi.nlm.nih.gov/pubmed/31017970
http://dx.doi.org/10.1371/journal.pone.0215537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481917/
https://www.ncbi.nlm.nih.gov/pubmed/31017970
http://dx.doi.org/10.1371/journal.pone.0215537

Ejemplares similares